Related by context. All words. (Click for frequent words.) 74 riociguat 72 MEND CABG 72 LUX Lung 72 Prospective Randomized 71 MAGE A3 ASCI 71 Refractory Angina 71 RE LY 71 Ocrelizumab 71 ExTRACT TIMI 71 APPRAISE 71 Natalizumab 70 clazosentan 70 CTAP# Capsules 70 Tumor Response 70 CIMZIA ™ 70 colorectal adenoma 70 Degarelix 70 phase IIIb 70 Carotid Revascularization Endarterectomy vs. 70 chronic thromboembolic pulmonary 70 Ranolazine 70 relapsed MM 70 efficacy endpoint 70 CHAMPION PCI 70 Restenosis 70 Oral Fingolimod 70 Non inferiority 70 randomized Phase IIb 70 Acute Decompensated Heart Failure 70 postoperative mortality 70 Microalbuminuria 70 BCIRG 70 VADT 70 multicenter randomized controlled 70 HER2 expression 70 recurrent glioblastoma multiforme 70 BRIM3 70 brivaracetam 69 Clinical Outcome 69 PSMA ADC 69 Safinamide 69 teriflunomide 69 Cardiotoxicity 69 GAMMAGARD 69 Acute Ischemic Stroke 69 REMINYL ® 69 hyperphenylalaninemia HPA due 69 ADVANCE PD 69 ximelagatran 69 ATACAND 69 CALGB # [001] 69 Ischemic 69 desvenlafaxine succinate 69 mertansine 69 Phase Ib clinical 69 HCV RESPOND 2 69 Subgroup analysis 69 Prostate AdenoCarcinoma Treatment 69 pharmacodynamic effects 69 cilostazol 69 morphometric vertebral fractures 69 Relapsing Remitting Multiple Sclerosis 69 CIMZIA TM certolizumab pegol 69 HER2 overexpression 69 Randomized Evaluation 69 oral FTY# 69 ARCOXIA 69 prospective multicentre 69 pain palliation 69 ACTEMRA TM 69 Xelox 69 Thrombolysis 69 Randomized Phase II 69 Tarceva TM 69 Dasatinib 69 placebo controlled clinical 69 symptomatic VTE 69 ZACTIMA 69 NATRECOR ® 69 Aromatase Inhibitors 69 atherogenic dyslipidemia 69 echocardiographic parameters 69 prucalopride 69 INCB# [003] 69 ADMIRE HF 69 multicenter Phase II 69 Randomized Double blind 69 ELACYT 69 CARE HF 69 AA Amyloidosis 69 Golimumab 69 multicentre randomized 69 RECORD1 69 Proteinuria 69 prospective multicenter study 69 See CLINICAL PHARMACOLOGY 68 serum phosphorous 68 NATRECOR R 68 transcranial Doppler ultrasound 68 HCV SPRINT 68 budesonide foam 68 Fondaparinux 68 Fibrillex TM 68 keloid scarring 68 MGd 68 Adjuvant Treatment 68 Prolongs Survival 68 novel VDA molecule 68 Diabetic Nephropathy 68 Phase Ib II 68 Enzastaurin 68 CYT# potent vascular disrupting 68 prospectively defined 68 BARI 2D 68 #F FDG PET 68 metastatic malignant 68 p# biomarker 68 Phase IIIb clinical 68 carotid artery stenting CAS 68 Ceplene/IL-2 68 RE LY ® 68 Cholesterol Levels SPARCL 68 ACOMPLIA R 68 phase IIb trial 68 ASTEROID 68 Primary endpoints 68 MEND CABG II 68 ToGA 68 phase Ib 68 HDL Selective Delipidation 68 Relapsing Multiple Sclerosis 68 Phase III Clinical Trial 68 elotuzumab 68 MERLIN TIMI 68 Randomized controlled 68 Androxal TM 68 Trandolapril 68 Zemplar Capsules 68 Betaferon R 68 GOUT 68 PRIMO CABG 68 TASKi3 68 IMPACT DCM 68 PROactive study 68 prospectively stratified 68 Outpatient Setting 68 rFVIIa 68 Intervention Effectiveness 68 thorough QT 68 androgen suppression 68 PFO migraine 68 Severe Sepsis 68 urinary N telopeptide 68 Hodgkin lymphoma HL 68 Hsp# Inhibitor 68 Hepatotoxicity 68 placebo controlled Phase 68 Aflibercept 68 Pivotal Clinical Trial 68 Angiox ® 68 QTc prolongation 68 adenoma recurrence 68 metastatic neuroendocrine tumors 68 Hypotension 68 HuMax EGFr 68 Critical Limb Ischemia CLI 68 Amrubicin 68 postoperative atrial fibrillation 68 gefitinib Iressa 68 Controlled Trial 68 APEX AMI trial 68 Randomized Study 68 AIM HIGH 68 Elocalcitol 68 relapsing remitting MS RRMS 67 Catheter Associated 67 Desvenlafaxine Succinate 67 Pivotal Trial 67 fosbretabulin 67 midstage clinical 67 Lp PLA 2 67 Randomized Phase 67 PAOD 67 paricalcitol 67 CIMZIA TM 67 PRADAXA 67 AVERROES 67 Angiographic 67 icatibant 67 Cardiovascular Outcomes 67 Hormone Refractory Prostate Cancer 67 Aggressive Reduction 67 colesevelam HCl 67 Combination REOLYSIN R 67 azilsartan medoxomil 67 ULORIC 67 cediranib 67 Phase IIB 67 Glufosfamide 67 Hepatocellular Carcinoma HCC 67 Percutaneous Coronary Intervention 67 Pivotal Phase 67 Randomized Controlled Trials 67 chronic idiopathic thrombocytopenic purpura 67 Phase 1a clinical 67 Carotid Stenting 67 intravascular hemolysis 67 Pivotal Phase III 67 ancrod 67 Cloretazine 67 sitaxsentan 67 variceal bleeding 67 pharmacokinetic PK 67 ALSYMPCA 67 ENDEAVOR IV 67 Venous Thromboembolism 67 Nesiritide 67 Adenoma Prevention 67 BRIM2 67 ER CHOP 67 FDG PET imaging 67 YONDELIS 67 NSABP B 67 RhuDex 67 phase IIb clinical 67 secondary efficacy endpoint 67 CIPN 67 CTEPH 67 BENICAR HCT 67 Pirfenidone 67 interferon gamma 1b 67 PERSEUS 67 sargramostim 67 thromboembolic 67 mg/m2 cohort 67 tramiprosate Alzhemed TM 67 Coronary Artery Bypass Graft 67 Secondary efficacy endpoints 67 F FDG PET 67 mg BID dose 67 Abciximab 67 Myocardial Perfusion Imaging 67 EURIDIS 67 ONTARGET 67 tanespimycin 67 phase IIa clinical 67 Phase Ib study 67 Complications Trial 67 confirmatory clinical 67 Initiated Phase 67 reduce serum phosphate 67 endometrial hyperplasia 67 Thromboembolism 67 Acute Coronary Syndromes 67 R# #mg BID 67 FOLPI 67 Ozarelix 67 myocardial necrosis 67 Acute Heart Failure 67 mITT population 67 JAK Inhibitor 67 Renal Cell Carcinoma RCC 67 Neoadjuvant 67 Pemetrexed 67 TRO# 67 Meets Primary Endpoint 67 Adult Stem Cell Therapy 67 complement inhibitor eculizumab 67 dose escalation phase 67 Breast Density 67 Erythropoietic therapies may 67 Nilotinib 67 ruboxistaurin 67 biliary tract cancer 67 invasive candidiasis 67 Subarachnoid hemorrhage 67 somatostatin analog 67 PEGylated interferon beta 1a 67 MYDICAR 67 PROMACTA 67 Phase 2b Clinical Trial 67 Stent Thrombosis 67 Predict Risk 67 Preclinical Models 67 R lenalidomide 67 oral rivaroxaban 67 sorafenib Nexavar 67 Candesartan 67 Skin sterol 67 symptomatic intracranial 67 randomized multicenter trial 67 Cardiac Resynchronization 67 Doxil ® 67 Bone Mineral Density 67 Dose escalation 66 NMIBC 66 evaluating tivozanib 66 cardiac repolarization 66 Prognostic Value 66 sunitinib malate 66 Long Term Efficacy 66 ZOLINZA 66 Teriflunomide 66 EGFR HER2 66 Echocardiographic 66 Hematologic 66 carotid endarterectomy CEA 66 TEMSO 66 pharmacokinetic PK study 66 Infarct 66 Val HeFT 66 candesartan cilexetil 66 cobiprostone 66 hematological parameters 66 SYNTAX trial 66 virological response 66 Sibutramine Cardiovascular Outcomes 66 Metastatic Prostate Cancer 66 Fulvestrant 66 Aliskiren 66 ARIXTRA 66 Prospective Multicenter 66 trial evaluating PRX# 66 Endothelial dysfunction 66 enzastaurin 66 Tasimelteon 66 number NCT# ClinicalTrials.gov 66 chemoprevention trials 66 CALGB # [002] 66 Hepatocellular Carcinoma 66 Patient Outcomes 66 Chronic Heart Failure 66 Estrogen Receptor 66 MIST II 66 glycated hemoglobin levels 66 Phase 1b clinical trials 66 eculizumab therapy 66 Tolvaptan 66 Hyperlipidemia 66 BrachySil TM 66 endothelin antagonists 66 Phase IIIb study 66 liver transplant recipients 66 Dapagliflozin 66 ABSORB trial 66 multicenter randomized clinical 66 postoperative chemotherapy 66 Clinical Trial Results 66 Drug eluting stent 66 exploratory endpoints 66 Silodosin 66 PRoFESS 66 serum phosphate 66 Solid Tumors 66 rilonacept 66 angiographic outcomes 66 EVEREST II 66 epoetin alpha 66 Tavocept 66 evaluating mipomersen 66 assessing T DM1 66 cinacalcet 66 ENDEAVOR III 66 CombAT 66 TACI Ig 66 multicenter prospective 66 Immunotherapeutic 66 Platelet Inhibition 66 Decompensated Heart Failure 66 EchoCRT 66 Achieves Primary Endpoint 66 Metastatic Melanoma 66 Denufosol 66 Study Evaluating 66 dyslipidaemia 66 Kepivance 66 Vimpat R 66 Recurrent Stroke 66 liver resection 66 bovine thrombin 66 RIO Lipids 66 metastatic GIST 66 nonrandomized 66 haematologic 66 Efficacy Results 66 opioid induced bowel dysfunction 66 Acute Myocardial Infarction 66 serum triglycerides 66 recurrent VTE 66 Stenting Trial CREST 66 Ophena TM 66 Randomized Clinical Trial 66 DAPT 66 Atherosclerotic 66 CAMMS# 66 Atopic Dermatitis 66 Phase IIb III 66 RSD# oral 66 terlipressin 66 Cystatin C 66 definite stent thrombosis 66 GORE TAG Device 66 Benign Prostatic Hyperplasia 66 blinded randomized 66 AZILECT R 66 Hydroxyurea 66 velafermin 66 evaluating Actimmune 66 CHARM Added 66 cerebral vasospasm 66 Cimzia TM 66 dosing cohort 66 Aortic Stenosis 66 Dose Ranging Study 66 TORISEL 66 Bezielle 66 Afatinib 66 KRAS status 66 Dyloject TM 66 dipyridamole plus 66 Antitumor 66 CRMD# 66 ibandronate 66 Albuminuria 66 Malignant Glioma 66 diarrhea predominant irritable 66 stratifying patients 66 K ras mutations 66 NEVO 66 Pioglitazone 66 OPT CHF 66 bepotastine besilate nasal spray 66 neratinib 66 Left Ventricular Dysfunction 66 TAXUS Liberte Long 66 vidofludimus 66 antitumor effect 66 EXJADE 66 thalidomide Thalomid 66 EMPHASIS HF trial 66 Multicenter 66 phase IIb study 66 Pooled Analysis 66 Interferon beta 1a 66 efalizumab 66 eplerenone 66 Ophena 66 phase IIa 66 Myocardial Ischemia 66 aminotransferase 66 randomized multicenter Phase III 66 ECASS 66 GW# [003] 66 Vernakalant 66 Liraglutide Effect 66 Randomised 66 lactate dehydrogenase LDH 66 Zarnestra 66 elacytarabine 66 IMPACT IMmunotherapy 66 Plicera 66 deferiprone 66 eprotirome 66 Malignant Melanoma 66 Aplidin 66 INSPIRE Trial Phase III 66 AVADO 66 Intervention Trial 66 Toremifene 66 PANVAC VF 66 Inflammatory Markers 66 lomitapide 66 PHPT 66 EXPLORE Xa 66 endometriosis ovarian cysts 66 Traficet EN 66 Antitumor Activity 66 Fabry Disease 66 HeFH 65 XIENCE V PROMUS Stent 65 Screening Trial 65 plasma kallikrein inhibitor 65 Sorafenib HCC Assessment 65 PSADT 65 Septic Shock 65 clevidipine 65 thromboembolic disease 65 intima media thickness 65 nab paclitaxel 65 specific antigen PSA 65 TOLAMBA 65 CALGB 65 Arranon 65 ACUITY trial 65 arterial thrombosis 65 Raloxifene STAR 65 Tasigna prolongs 65 Vitaxin 65 SORT OUT III 65 PRIMO CABG2 65 PCI ExTRACT TIMI 65 Sirolimus eluting Coronary Stent 65 bazedoxifene conjugated estrogens 65 Factor VIIa 65 PRE SURGE 65 binary restenosis 65 pharmacodynamic parameters 65 KRN# 65 Darapladib 65 Levels Linked 65 Cilostazol 65 Cognitive Impairment 65 stage IIIb IV 65 Virulizin ® 65 Phase III ADT 65 TG MV 65 CINQUIL 65 tramiprosate ALZHEMED TM 65 Rilonacept 65 forodesine 65 plasma pharmacokinetics 65 alvespimycin 65 reslizumab 65 deCODE AF TM 65 PLCO trial 65 ANCHOR trial 65 AZILECT ® 65 leiomyomas 65 Betaferon ® 65 CAPHOSOL 65 OMNARIS Nasal Spray 65 Diabetic Macular Edema 65 selective modulator 65 Allogeneic 65 Pharmacodynamic 65 EXPAREL ™ 65 LYSTEDA 65 NEVO ™ 65 Diabetes ACCORD 65 Initiate Phase 65 Triolex 65 pivotal bioequivalence 65 Monotherapy 65 Acute Coronary Syndrome 65 MoxDuo TM IR 65 secondary efficacy endpoints 65 multicenter multinational 65 Azacitidine 65 Adjuvant chemotherapy 65 irbesartan 65 pertuzumab 65 Follicular Lymphoma 65 tarenflurbil 65 Phase III Pivotal 65 romiplostim 65 serum calcium levels 65 ONCONASE R 65 everolimus eluting stents 65 Pulmonary Arterial Hypertension 65 esophageal carcinoma 65 lucinactant 65 postoperative morbidity 65 SIMPADICO 65 pharmacodynamic PD 65 dose cohort 65 receptor tyrosine kinase inhibitor 65 Phase Ib Clinical Trial 65 FASLODEX 65 antiplatelet agent 65 AGHD 65 Catena ® 65 Adjuvant Therapy 65 CLARITY study 65 MADIT II 65 tocilizumab 65 Raptiva R 65 eltrombopag 65 Temsirolimus 65 Coronary CTA 65 chemoradiotherapy 65 Mg Usa 65 Nuvion 65 vernakalant hydrochloride 65 Diabetic Foot Ulcer 65 Urocortin 2 65 multicenter placebo controlled 65 periprocedural 65 mTOR kinase 65 Localized Prostate Cancer 65 Procoralan 65 Diabetic Neuropathy 65 Cholinesterase Inhibitors 65 platelet reactivity 65 unfractionated heparin UFH 65 Novel Oral 65 hemostatic efficacy 65 prospective multicenter randomized 65 invasive aspergillosis 65 antiangiogenic therapy 65 antioxidant supplementation 65 TLK# 65 TASKi2 65 lipoprotein Lp 65 adjuvant radiotherapy 65 ThermoDox ® clinical 65 Dose Escalation 65 Vandetanib 65 Ischemic Stroke 65 Prestara 65 APTIVUS 65 PEGINTRON TM 65 multicentre prospective 65 Bivalirudin 65 PLX STROKE targeting 65 CYP#A# substrate 65 Corus CAD 65 ENDEAVOR II 65 hyperoxaluria 65 Dacogen decitabine 65 Systemic Sclerosis 65 solifenacin 65 Nonalcoholic Fatty Liver Disease 65 Cardiovascular Risk 65 Breast Cancer Recurrence 65 APTIVUS r 65 Phase IIb clinical trials 65 idraparinux 65 Bayer HealthCare Onyx Pharmaceuticals 65 Aurora Kinase 65 EDEMA3 65 TIMP 1 65 AST ALT 65 Completes Patient Enrollment 65 BEXXAR Therapeutic Regimen 65 dual endothelin receptor antagonist 65 multicenter randomized placebo controlled 65 corticosteroid dose 65 Phase 2b Trial 65 tesmilifene 65 adenomatous 65 galiximab 65 zotarolimus 65 Nocturia 65 adjuvant GIST 65 sunitinib Sutent 65 Hypoactive Sexual Desire Disorder 65 First Patient Enrolled 65 LUMINATE 65 cytoreductive nephrectomy 65 Phase #b/#a clinical 65 Elagolix 65 Interferon Beta 65 PREVENT IV 65 trastuzumab DM1 T DM1 65 ST Segment Elevation 65 recurrent venous thromboembolism 65 goserelin 65 nalbuphine ER 65 atherothrombotic disease 65 posaconazole 65 Patency 65 subclinical hypothyroidism 65 Rosuvastatin 65 RoACTEMRA 65 GEM OS1 65 Triapine R 65 FOLOTYN ® 65 renal biopsy 65 renal artery stenting 65 Randomized Double Blind 65 Akt activation 65 APEX PD 65 GLIADEL R Wafer 65 J Am Coll 65 alvimopan 65 Archexin 65 Endometrial 65 Anti Bacterial Envelope 65 Clinical Antipsychotic Trials 65 Gastric Cancer 65 GRNCM1 65 HYVET 65 Decitabine 65 Patients Treated With 65 SPIRIT FIRST 65 SNT MC# 65 Phase III Clinical Trials 65 unresectable tumors 65 placebo controlled Phase III 65 severe hypercholesterolemia 65 mycophenolate mofetil 65 Confirmatory 65 EMPOWER ™ 65 perioperative morbidity 65 LHRH receptor positive 65 UACR 65 Xanafide 65 APTIMA HPV 65 Anthracycline 65 pharmacodynamic markers 65 Metastatic Renal Cell Carcinoma 65 carotid IMT 65 ON #.Na 65 Lymphocytic 65 Relapsed Multiple Myeloma 65 Treating Chronic 65 AEGR 65 Gastrointestinal Stromal Tumors 65 SPRYCEL ® 65 adalimumab Humira 65 Synta Announces 65 PLCO 65 ACTIVE W 65 Phase 2a Clinical Trial 65 cangrelor 65 Mycophenolate Mofetil 65 randomized multicenter 65 carotid artery stenting 65 antithrombotic therapy 65 multicentric 65 chemoradiation therapy 65 achieved CCyR 65 GnRH agonists 65 substudy 65 canakinumab 65 GFT# 65 CYPHER Stent 65 SYMMETRY trial 65 CIN2 + 65 Tanespimycin 65 CYT# QbG# 65 Saxagliptin 65 ZD# [001] 65 CABG Surgery 65 EDEMA3 trial 65 Serdolect ® 65 Successfully Completes Phase 65 Lubiprostone 65 Adenomas 65 neoadjuvant treatment 65 T2DM 65 ENESTnd 65 concurrent chemoradiation 65 Coronary artery bypass grafting 65 ACCORD Lipid 65 Pertuzumab 65 LibiGel ® 65 standard chemotherapy regimen 65 liposomal doxorubicin 65 HGPIN 65 TTF Therapy 65 kidney urologic 65 trastuzumab DM1 65 NSABP 65 relapsed MCL 65 selenium supplementation 65 beta blocker therapy 65 TAXUS Liberté stent 65 Abiraterone Acetate 65 oncologic outcomes 65 axitinib 65 hypervascular tumors 65 HoFH 65 MEVACOR 65 liposomal amphotericin B 65 hematologic parameters 65 sipuleucel T 65 homocysteine concentrations 65 Tyrosine Kinase Inhibitor 65 Bicifadine 65 Dacogen injection 65 STEP BD 65 CUSTOM III 65 grade cervical intraepithelial 65 Embolic Protection Device 65 NPM1 mutation 65 dose atorvastatin 65 TAXUS Stent 65 atherothrombotic events 65 AGILECT ® 65 randomized controlled Phase 65 Clinical Trial Data 65 Lenalidomide 65 PROSTVAC VF 65 colorectal liver metastases 65 BYSTOLIC 65 hematopoietic cancers 65 calculated creatinine clearance 65 pharmacodynamic properties 65 Eluting Stent 65 registrational Phase 65 Evaluation WISE 65 ALN HPN 65 pediatric malignancies 65 Hematological 65 figitumumab 65 EDARBI 65 sleeve lobectomy 65 Dabigatran etexilate 65 dose escalation clinical 65 Dupuytren Contracture 65 percutaneous transluminal coronary angioplasty 65 thromboembolism 65 carotid atherosclerosis 65 Cimzia ® certolizumab pegol 65 metaglidasen 65 Recurrent Breast Cancer 65 Inhaled nitric oxide 65 Renal Function 65 Tocilizumab 64 bezafibrate 64 Fracture Risk 64 Edge STudy 64 Castration Resistant Prostate Cancer 64 tolerability pharmacokinetics 64 PCWP 64 fluvastatin 64 Stent Restenosis 64 patients undergoing CABG 64 mGluR2 NAM 64 advanced adenoma 64 COPERNICUS 64 LymphoStat B belimumab 64 JAK2 Inhibitor 64 glycosylated hemoglobin HbA1c 64 Octreolin 64 Thorough QT 64 Active Ulcerative Colitis 64 Diamyd r 64 systemic anaplastic large 64 platelet inhibition 64 Risk Stratification 64 Bucindolol 64 Multicenter Phase 64 TBC# 64 Corgentin 64 Glypromate 64 thyrotropin 64 corticosteroid dexamethasone 64 Cardiopulmonary bypass 64 palifermin 64 recurrent NSCLC 64 cinacalcet HCl 64 ritonavir boosted 64 Stenting Trial 64 Demonstrates Sustained 64 VAPRISOL 64 mRCC 64 Double Blind Randomized 64 Myocardial Infarction Study 64 Oral Calcitonin 64 Serious Infections 64 thromboembolic events 64 Advanced Melanoma 64 TWYNSTA 64 ORENCIA ® 64 Egrifta 64 multicenter trials 64 ACTOS ® 64 HMG CoA reductase inhibitors 64 ARIXTRA R 64 HF ACTION 64 Subgroup Analysis 64 Subgroup analyzes 64 Phase 2b Study 64 AEG# 64 afatinib 64 rALLy clinical trial 64 Exelixis XL# 64 vildagliptin 64 thromboembolic complications 64 pulmonary metastases 64 Cleviprex TM clevidipine 64 hepatocellular carcinoma liver 64 NSABP C 64 recurrent metastatic 64 eritoran 64 Stage IIB 64 vorinostat 64 Eltrombopag 64 myocardial ischemia 64 Bosentan 64 CYPHER R Sirolimus eluting 64 iniparib 64 Pelvic Organ Prolapse 64 TNF Tumor Necrosis Factor 64 Lu AA# 64 subgroup analyzes 64 samalizumab 64 CCX# B 64 upper gastrointestinal bleeding 64 colorectal carcinoma 64 vaso occlusive crisis 64 psoriatic arthritis PsA 64 Prostate Cancer Prevention 64 ALA PDT 64 Celebrex celecoxib 64 INTEGRILIN 64 Lung Cancer Trial 64 bronchial hyperresponsiveness 64 ILLUMINATE 64 REVIVE Diabetes 64 Multiple Ascending Dose 64 Nicotine Vaccine 64 Ataluren 64 ISTODAX 64 CIMZIA R 64 CBLC# 64 elevated ALT 64 AGILECT R 64 NEUVENGE 64 Myelodysplastic Syndromes 64 Unstable Angina 64 intravesical therapy 64 intermittent dosing 64 periprocedural MI 64 Vascugel ® 64 LAB CGRP 64 COSTAR II 64 Femara letrozole 64 intensive statin therapy 64 6R BH4 64 artery stenosis 64 Orazol 64 SUTENT ® 64 glycated hemoglobin HbA1c 64 Hypertriglyceridemia 64 BrachySil ™ 64 macroalbuminuria 64 Remission Maintenance 64 Intravitreal 64 genotypic resistance 64 Hb A1C 64 Patients Receiving 64 PROMUS R 64 Tiotropium 64 treat benign prostatic 64 neurologic progression 64 RECIST Response Evaluation Criteria 64 prolonged QT interval 64 biochemical relapse 64 composite endpoint 64 neoadjuvant therapy 64 Folfox 64 IIIa inhibitor 64 multicenter phase 64 recurrent malignant glioma 64 Myelodysplastic Syndrome 64 thyroglobulin 64 serum uric acid sUA 64 ATL# [001] 64 RhuDex R 64 Vascugel 64 paroxetine Paxil 64 PIX# [002] 64 Nexavar sorafenib 64 controlled multicenter Phase 64 metastatic colorectal carcinoma 64 vandetanib 64 acyclovir Lauriad R 64 multicenter Phase III 64 Tigecycline 64 Pegloticase 64 Anticoagulation 64 Intervention Trial GAIT 64 ductal carcinomas 64 PROSTVAC TM 64 Epirubicin 64 enoximone 64 PRESEPT 64 TREDAPTIVE 64 PDX pralatrexate 64 IMA# 64 Cytogenetic 64 Rezular 64 Renal Cell Carcinoma 64 Motesanib 64 Microplasmin 64 NEO3 64 Parathyroid Hormone 64 metastatic colorectal 64 Heterozygous Familial Hypercholesterolemia 64 ABCSG 64 Iron Deficiency Anemia 64 Surgical Treatment 64 Onrigin 64 stage IIIB 64 Naive Patients 64 Adjuvant Chemotherapy 64 antiarrhythmic drug 64 Celecoxib APC trial 64 Shows Statistically Significant 64 aurora kinase 64 perioperative mortality 64 Ozurdex 64 Second Pivotal Phase 64 β blockers 64 trastuzumab emtansine T DM1 64 endometrial carcinoma